Publications

PanCareLife

PanCareLIFE was a 5-year (2013-8) EU Framework 7 Programme in the Health Theme that studied the impact of treatment regimes on the long-term health of childhood cancer survivors. Specifically, PanCareLIFE evaluated the risks of impairments in female fertility, in hearing, and in quality of life. PanCareLIFE also developed two guidelines for fertility preservation, and will disseminate widely the results from this project. Below an overview of publications that were made within the PanCareLIFE project.

  1. van der Kooi ALF, Clemens E, Broer L, Zolk O, Byrne J, Campbell H, Berger CB, Calaminus G, Dirksen U, Ranft A, Falck Winther J, Fosså SD, Grabow D, Haupt R, Kaiser M, Kepak T, Kruseova J, Modan-Moses D, Spix C, Kaatsch P, Laven JSE, van Dulmen-den Broeder E, Uitterlinden AG, van den Heuvel-Eibrink MM on behalf of the PanCareLIFE Consortium:
    Genetic variation in gonadal impairment in female survivors of childhood cancer: design of a PanCareLIFE study. BMC Cancer 18, 930. doi: 10.1186/s12885-018-4834-3, 2018.
  1. Byrne J, Grabow D, Campbell H, O’Brien K, Bielack S, am Zehnhoff-Dinnesen A, Calaminus G, Kremer L, Langer T, van den Heuvel-Eibrink M,  van Dulmen-den Broeder E, Baust K, Bautz A, Beck J, Berger C, Binder H, Borgmann-Staudt A, Broer L, Cario H, Casagranda L, Clemens E, Deuster D, de Vries A, Dirksen U, Falck Winther J, Font-Gonzalez A, Fossa S, Grandage V, Haupt R, Hecker-Nolting S, Hjorth L, Kaiser M, Kenborg L, Kepak T, Kepakova K, Knudsen L, Krawczuk-Rybak M,  Kruseova J, Kuehni CE, , Kunstreich M, Kuonen R,  Lackner H, Leiper A, Loeffen E,  Luks A, Modan-Moses D, Mulder R, Parfitt R, Paul N, Ranft A, Ruud E, Schilling R, Spix C, Stefanowicz J, Strauβ G, Uitterlinden A,  van den Berg M, van der Kooi AL, van Dijk M,  van Leeuwen F, Zolk O, Zoller D, Kaatsch P on behalf of the PanCareLIFE Consortium:
    PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity, and health related quality of life after cancer occurring among children and adolescents. Eur J Cancer 103, 227-237, 2018.
  1. van den Berg M, van Dijk M, Byrne J, Campbell H, Berger C, Borgmann-Staudt A, Calaminus G, Dirksen U, Winther JF, Fossa SD, Grabow D, Grandage VL, van den Heuvel-Eibrink MM, Kaiser M, Kepak T, Kremer LC, Kruseova J, Kuehni CE, Lambalk CB, van Leeuwen FE, Leiper A, Modan-Moses D, Morsellino V, Spix C, Kaatsch P, van Dulmen-den Broeder E:
    Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE). JMIR Res Protoc 7, e10824, 2018.
  1. Clemens E, Meijer AJ, Broer L, Langer T, van der Kooi AL, Uitterlinden AG, de Vries A, Kuehni CE, Garrè ML, Kepak T, Kruseova J, Winther JF, Kremer LC, van Dulmen-den Broeder E, Tissing WJ, Rechnitzer C, Kenborg L, Hasle H, Grabow D, Parfitt R, Binder H, Carleton BC, Byrne J, Kaatsch P, Am Zehnhoff-Dinnesen A, Zolk O, van den Heuvel-Eibrink MM:
    Genetic determinants of ototoxicity during and after childhood cancer treatment: protocol for the PanCareLIFE study. JMIR Res Protoc 8, e11868, 2019.
  1. Clemens E, Broer L, Langer T, Uitterlinden AG, de Vries ACH, van Grotel M, Pluijm SFM, Binder H, Byrne J, Broeder EVD, Crocco M, Grabow D, Kaatsch P, Kaiser M, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, van der Kooi AF, Kremer LC, Kruseova J, Kuehni CE, van der Pal H, Parfitt R, Deuster D, Matulat P, Spix C, Tillmanns A, Tissing WJE, Maier L, Am Zehnhoff-Dinnesen A, Zolk O, van den Heuvel-Eibrink MM on behalf of the PanCareLIFE consortium:
    Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study. Pharmacogenomics J 20, 294–305, 2020. doi.org/10.1038/s41397-019-0113-1
  1. Langer T, Clemens E, Broer L, Maier L, Uitterlinden AG, de Vries ACH, van Grotel M, Pluijm SFM, Binder H, Mayer B, von dem Knesebeck A, Byrne J, van Dulmen-den Broeder E, Crocco M, Grabow D, Kaatsch P, Kaiser M, Spix C, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, van der Kooi AF, Kremer LC, Kruseova J, Bielack S, Sorg B, Hecker-Nolting S, Kuehni CE, Ansari M, Kompis M, van der Pal HJ, Parfitt R, Deuster D, Matulat P, Tillmanns A, Tissing WJE, Beck JD, Elsner S, Am Zehnhoff-Dinnesen A, van den Heuvel-Eibrink MM, Zolk O on behalf of the PanCareLIFE consortium:
    Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data in Brief 32:106227, 2020. doi: 10.1016/j.dib.2020.106227. eCollection 2020 Oct. PMID: 32939381 Free PMC article
  1. Langer T, Clemens E, Broer L, Maier L, Uitterlinden AG, de Vries ACH, van Grotel M, Pluijm SFM, Binder H, Mayer B, von dem Knesebeck A, Byrne J, van Dulmen-den Broeder E, Crocco M, Grabow D, Kaatsch P, Kaiser M, Spix C, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, van der Kooi AF, Kremer LC, Kruseova J, Bielack S, Sorg B, Hecker-Nolting S, Kuehni CE, Ansari M, Kompis M, van der Pal H, Parfitt R, Deuster D, Matulat P, Tillmanns A, Tissing WJE, Beck JD, Elsner S, Am Zehnhoff-Dinnesen A, van den Heuvel-Eibrink MM, Zolk O on behalf of the PanCareLIFE consortium:
    Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study. Eur J Cancer. 138, 212-224, 2020. doi: 10.1016/j.ejca.2020.07.019.
  1. van der Kooi, van Dijk M, Broer L, van den Berg MH, Laven JSE, van Leeuwen FE, Lambalk CB, Overbeek A, Loonen JJ, van der Pal HJ, Tissing WJ, Versluys B, Bresters D, Beerendonk CCM, Ronckers CR, van der Heiden-van der Loo M, Kaspers GL, de Vries ACH, Robison LL, Hudson MH, Chemaitilly W, Byrne J, Berger C, Clemens E, Dirksen U, Winther JF, Fosså SD, Grabow D, Haupt R, Kaiser M, Kepak T, Kruseova J, Modan-Moses D, Pluijm SMF, Spix C, Zolk O, Kaatsch P, Krijthe JH, Kremer LC, Yasui Y, Brooke RJ, Uitterlinden AG, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E on behalf of the DCOG LATER-VEVO study group, the PanCareLIFE Consortium and the St. Jude Lifetime Cohort study:
    Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function, Human Reproduction deaa342, 2021. https://doi.org/10.1093/humrep/deaa342.
  1. Calaminus G, Baust K, Berger C, Byrne J, Binder H, Casagranda L, Grabow D, Grootenhuis M, Kaatsch P, Kaiser M, Kepak T, Kepakova K, Kremer LC, Kruseova J, Luks A, Spix C, van den Berg M, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, Kuonen R, Sommer G, Kuehni C:
    Health-related quality of life in European childhood cancer survivors: protocol for a study within PanCareLIFE . JMIR Res Protoc 2021, 10: e21851
  1. H. van den Berg, M. van Dijk, J. Byrne, C. Berger, U. Dirksen, J.F. Winther, S.D. Fossa, D. Grabow, V.L. Grandage, R. Haupt, M.M. van den Heuvel-Eibrink, M. Kaiser, T. Kepak, A.L.F. van der Kooi, L.C.M. Kremer, J. Kruseova, C.B. Lambalk, F.E. van Leeuwen, A. Leiper, D. Modan-Moses, C. Spix, J.W.R. Twisk, C.M. Ronckers, P. Kaatsch, E. van Dulmen-den Broeder, on behalf of the PanCareLIFE Consortium:
    Treatment-related fertility impairment in long-term female childhood, adolescent and young adult cancer survivors: investigating dose-effect relationships in a European case-control study (PanCareLIFE). Human Reproduction 0:1–13. 2021. doi: 10.1093/humrep/deab035.
  1. Mulder, Renée L, Berger, Claire et al.:
    Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. The Lancet Oncology 22, e45 – e56, 2021.
  1. Mulder, Renée L, Berger, Claire et al:
    Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. The Lancet Oncology 22, e57 – e67, 2021.
  1. Mulder, Renée L, Anderson, Richard A et al:
    Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. The Lancet Oncology 22, e68 – e80, 2021.
  1. Kaatsch P, Byrne J, Grabow D on behalf of the PanCareLIFE Consortium:
    Managing a pan-European consortium on late effects among long-term survivors of childhood and adolescent cancer – the PanCareLIFE project. Int J Environ Res Public Health 2021, 18, 3918. https://doi.org/10.3390/ijerph18083918.
  1. Meijer AJM, Diepstraten FA, Langer T, Broer L, Domingo IK, Clemens E, Uitterlinden AG, de Vries ACH3, van Grotel M, Vermeij WP, Ozinga RA ,Binder H, Byrne J, van Dulmen-den Broeder E, Garrè ML, Grabow D, Kaatsch P, Kaiser M, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, Kepakova K, Tissing WJE, van der Kooi ALF, Kremer LC, J Kruseova J, Pluijm SMF, Kuehni CE, van der Pal H, Parfit R, Spix C, Tillmanns A, Deuster D, Matulat P, Calaminus G, Hoetink AE, Elsner S, Gebauer J, R Haupt, Lackner H, Blattmann C, Neggers SJCMM, Rassekh SR, Wright GEB, Brooks B, Nagtegaal AP, Drögemöller BI, Ross CJD, Bhavsar AP, am Zehnhoff-Dinnesen A, Carleton BC, Zolk O, van den Heuvel-Eibrink MM, the PanCareLIFE consortium and the CPNDS Consortium.
    TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ Precision Oncology; 5:64: February 2021.